Leana Wen
CIK: 0001847598
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (12 total)
- Jul 31, 2026GKOS
GLAUKOS Corp
Sale(S)Direct525 shares at avg. $167.63$88K - Jun 22, 2026URGN
UroGen Pharma Ltd.
Award(A)DirectRestricted Stock Unit
8K shares- - Jun 22, 2026URGN
UroGen Pharma Ltd.
Award(A)DirectStock Option (right ot buy)
10K shares- - May 28, 2026GKOS
GLAUKOS Corp
Award(A)DirectStock Option (Right to Buy)
3K shares- - May 28, 2026GKOS
GLAUKOS Corp
Award(A)Direct1.9K shares- - May 1, 2026GKOS
GLAUKOS Corp
Sale(S)Direct1.7K shares at avg. $143.35$244K - Jan 2, 2026GKOS
GLAUKOS Corp
Award(A)Direct623 shares- - Nov 26, 2025URGN
UroGen Pharma Ltd.
Exercise(M)Direct2K shares- - Aug 26, 2025URGN
UroGen Pharma Ltd.
Award(A)DirectRestricted Stock Unit
8K shares- - Aug 26, 2025URGN
UroGen Pharma Ltd.
Award(A)DirectStock Option (right ot buy)
10K shares- - May 29, 2025GKOS
GLAUKOS Corp
Award(A)Direct2.1K shares- - Jan 2, 2025GKOS
GLAUKOS Corp
Award(A)Direct461 shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 31, 2026 |  GKOS GLAUKOS Corp | Sale(S) | 525 | $167.63 | $88,006 | Direct |
| Jun 22, 2026 |  URGN UroGen Pharma Ltd. | Award(A) Restricted Stock Unit | 8,000 | - | - | Direct |
| Jun 22, 2026 | URGN UroGen Pharma Ltd. | Award(A) Stock Option (right ot buy) | 10,000 | - | - | Direct |
| May 28, 2026 | GKOS GLAUKOS Corp | Award(A) Stock Option (Right to Buy) | 2,987 | - | - | Direct |
| May 28, 2026 | GKOS GLAUKOS Corp | Award(A) | 1,878 | - | $0 | Direct |
| May 1, 2026 | GKOS GLAUKOS Corp | Sale(S) | 1,700 | $143.35 | $243,695 | Direct |
| Jan 2, 2026 | GKOS GLAUKOS Corp | Award(A) | 623 | - | $0 | Direct |
| Nov 26, 2025 | URGN UroGen Pharma Ltd. | Exercise(M) | 2,000 | - | - | Direct |
| Aug 26, 2025 | URGN UroGen Pharma Ltd. | Award(A) Restricted Stock Unit | 8,000 | - | - | Direct |
| Aug 26, 2025 | URGN UroGen Pharma Ltd. | Award(A) Stock Option (right ot buy) | 10,000 | - | - | Direct |
| May 29, 2025 | GKOS GLAUKOS Corp | Award(A) | 2,108 | - | - | Direct |
| Jan 2, 2025 | GKOS GLAUKOS Corp | Award(A) | 461 | - | - | Direct |
1-12 of 12 transactions
About WEN LEANA
WEN LEANA (SEC CIK 0001847598) files insider reports with the SEC as Director of GLAUKOS Corp (GKOS) and Director of UroGen Pharma Ltd. (URGN).
Signal8 holds 9 ownership filings by WEN LEANA, all Form 4s, filed between Jun 2, 2025 and Aug 3, 2026. Those filings report 12 transactions, from Jan 2, 2025 to Jul 31, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on WEN LEANA's filings is in ALISO VIEJO, CA.
Recent filings by WEN LEANA
- Jul 31, 2026: Open-market sale of GKOS shares (Form 4, code S).
- Jun 22, 2026: Grants or awards of URGN derivative securities (2 lines, Form 4, code A).
- May 28, 2026: Grants or awards of GKOS derivative securities (2 lines, Form 4, code A).
- May 1, 2026: Open-market sale of GKOS shares (Form 4, code S).
- Jan 2, 2026: Grant or award of GKOS shares (Form 4, code A).
Other insiders filing for GLAUKOS Corp (GKOS)
- Navratil Tomas, CHIEF DEVELOPMENT OFFICER
- Kliman Gilbert H, Director
- Gilliam Joseph E, PRESIDENT & COO
- Thurman Alex R., SVP & CHIEF FINANCIAL OFFICER
- Burns Thomas William, CHAIRMAN & CEO
- Foley Mark J, Director